AllSci News
Cell study uncovers polyamines as natural ferroptosis defense
Polyamines — small, positively charged metabolites long studied for roles in cell growth and translation — directly chelate labile intracellular iron and...
Aizen lands multi-program oral peptide deal worth up to USD 100m per target
San Diego-based Aizen Therapeutics has entered a multi-program collaboration with an undisclosed San Diego-based public biotech to apply its DaX artificial...
Silence Therapeutics completes private fund raise at USD 201.3m for divesiran trial
UK-based Silence Therapeutics plc (Nasdaq: SLN) announced the closing of an upsized public offering of American Depositary Shares (ADSs), raising...
Sandoz expands Henlius partnership to cover up to 10 biosimilars for USD 322m
Shanghai Henlius Biotech (HKEX: 2696) and Sandoz (SIX: SDZ; OTCQX: SDZNY) have expanded their biosimilars collaboration into a platform-level deal covering...
argenx's Vyvgart Hytrulo delivers first Phase III success in IMNM
Efgartigimod alfa and hyaluronidase-qvfc met the primary endpoint of a Phase III trial in autoimmune myositis, delivering the first statistically...
Tagrisso plus Orpathys extends OS in MET-resistant EGFR-mutated lung cancer
The SAFFRON Phase III trial has delivered the first global Phase III evidence that a targeted oral combination can improve both progression-free and overall...
Voyager registers first-in-human trial of tau-silencing gene therapy VY1706 in Alzheimer’s
Voyager Therapeutics (Nasdaq: VYGR) has registered a Phase I VY1706 clinical trial in early Alzheimer's disease, marking the first time an adeno-associated...
China moves quickly on ICH E6(R3) Annex 2 with March applicability date
Category: Clinical Trial Reform | Regulatory Body: NMPA (CDE) | Geography: China | Instrument: Guidance document
China NMPA sets framework for direct role in national R&D funding
Category: Research Policy | Regulatory Body: NMPA (National Medical Products Administration) | Geography: China | Policy Instrument: Guidance document
Redx takes control of Skye in Nasdaq combination backed by USD 125m financing
San Diego-based Skye Bioscience, Inc. (Nasdaq: SKYE) announced a definitive agreement to acquire UK-based Redx Pharma Limited alongside USD 125 million in...
Fate takes off-the-shelf CAR T into potentially registrational lupus nephritis trial
Fate Therapeutics (Nasdaq: FATE) has dosed the first patient in RECLAIM-LN, its Phase II potentially registrational trial of FT819, an off-the-shelf...
MGH, Harvard researchers restore PV neuron function, suppress seizures in NDD mouse model
A single transcription factor delivered to a specific class of inhibitory neurons in adult mice rescues seizures, restores hippocampal network oscillations,...
Synthetic glycan opens vaccine route against Candida auris
A single chemically synthesized sugar molecule can both vaccinate against and detect Candida auris, the multidrug-resistant fungal pathogen responsible for...
US FDA approves Lantheus’ Tauklarify as second tau PET tracer for Alzheimer’s disease
The US FDA has approved Tauklarify (florquinitau F 18 injection, also known as MK-6240), a radiodiagnostic positron emission tomography (PET) agent for...
Oculogenex secures NEI grant as AMD gene therapy nears IND
Oculogenex, a La Habra, California-based gene therapy company, has received a USD 1.09 million R44 SBIR grant from the National Eye Institute (NEI) to...
The AllSci Brief
Free, systematic R&D and deal news. Daily.